Allarity Therapeutics receives USPTO Notice of Allowance for stenoparib DRP companion diagnostic patent

Allarity Therapeutics, Inc.

Notice of Allowance covers multiple claims for methods predicting clinical benefit and patient selection via gene expression.
Patent expected to be granted within three months; would provide exclusivity at least into 2039 for stenoparib with DRP test.
Allarity previously secured European and Australian patents for Stenoparib DRP; holds 18 granted patents for other drug-specific DRPs.
Patent applications for Stenoparib DRP remain pending in Canada, Japan, China, and India.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.